143 related articles for article (PubMed ID: 10365725)
41. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
42. Filgrastim in patients with neutropenia: potential effects on quality of life.
Lyman GH; Kuderer NM
Drugs; 2002; 62 Suppl 1():65-78. PubMed ID: 12479595
[TBL] [Abstract][Full Text] [Related]
43. [Use of granulocyte growth factors: recommendations of the Portuguese Society of Hematology].
Forjaz de Lacerda J; Leal da Costa F; Marques Pereira A; Príncipe F; Teixeira A; Parreira A;
Acta Med Port; 2008; 21(5):412-26. PubMed ID: 19187683
[TBL] [Abstract][Full Text] [Related]
44. Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathexis.
Cernelc P; Andoljsek D; Mlakar U; Pretnar J; Modic M; Zupan IP; Zver S
Pflugers Arch; 2000; 440(5 Suppl):R81-2. PubMed ID: 11005621
[TBL] [Abstract][Full Text] [Related]
45. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.
Morstyn G; Foote M; Perkins D; Vincent M
Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147
[TBL] [Abstract][Full Text] [Related]
46. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
47. [Biosimilar filgrastim: from development to record].
García Alfonso P
Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
[TBL] [Abstract][Full Text] [Related]
48. Long-term use of pegfilgrastim in children with severe congenital neutropenia: clinical and pharmacokinetic data.
Fioredda F; Lanza T; Gallicola F; Riccardi F; Lanciotti M; Mastrodicasa E; Signa S; Zanardi S; Calvillo M; Dufour C
Blood; 2016 Oct; 128(17):2178-2181. PubMed ID: 27621310
[No Abstract] [Full Text] [Related]
49. Neonatal sepsis with neutropenia: granulocyte-colony stimulating factor (G-CSF).
Silvinato A; Bernardo WM; Floriano I; Soledade GNB
Rev Assoc Med Bras (1992); 2020; 66(1):3-10. PubMed ID: 32130373
[No Abstract] [Full Text] [Related]
50. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
51. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
[TBL] [Abstract][Full Text] [Related]
52. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
Kubo K; Miyazaki Y; Murayama T; Shimazaki R; Usui N; Urabe A; Hotta T; Tamura K
Br J Haematol; 2016 Aug; 174(4):563-70. PubMed ID: 27072050
[TBL] [Abstract][Full Text] [Related]
53. Filgrastim: new indication. AIDS-associated neutropenia: another soft indication.
Prescrire Int; 2001 Aug; 10(54):106-7. PubMed ID: 11718177
[TBL] [Abstract][Full Text] [Related]
54. Neutropenia in an extremely premature infant treated with recombinant human granulocyte colony-stimulating factor.
Roberts RL; Szelc CM; Scates SM; Boyd MT; Soderstrom KM; Davis MW; Glaspy JA
Am J Dis Child; 1991 Jul; 145(7):808-12. PubMed ID: 1711773
[TBL] [Abstract][Full Text] [Related]
55. Negative design for improved therapeutic proteins.
Desjarlais JR; Lazar GA
Trends Biotechnol; 2003 Oct; 21(10):425-7. PubMed ID: 14512227
[No Abstract] [Full Text] [Related]
56. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y
J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
[TBL] [Abstract][Full Text] [Related]
57. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
Bongiovanni A; Monti M; Foca F; Recine F; Riva N; Di Iorio V; Liverani C; De Vita A; Miserocchi G; Mercatali L; Amadori D; Ibrahim T
Support Care Cancer; 2017 Jan; 25(1):111-117. PubMed ID: 27568305
[TBL] [Abstract][Full Text] [Related]
58. Bullous Sweet's syndrome in congenital neutropenia: association with pegfilgrastim.
Draper BK; Robbins JB; Stricklin GP
J Am Acad Dermatol; 2005 May; 52(5):901-5. PubMed ID: 15858487
[TBL] [Abstract][Full Text] [Related]
59. Recombinant human stem cell factor, a c-kit ligand, stimulates granulopoiesis in severe congenital neutropenia.
Ijima H; Shitara T; Yugami S; Sotomatu M; Kuroume T
Am J Hematol; 1993 Apr; 42(4):407. PubMed ID: 7684187
[No Abstract] [Full Text] [Related]
60. Hematopoietic growth factors: ESMO recommendations for the application.
; Greil R; Psenak O
Ann Oncol; 2007 Apr; 18 Suppl 2():ii89-91. PubMed ID: 17491063
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
